top of page

Free Biopharma Daily Stock Updates - 08/03/21

  • Writer: BPIQ
    BPIQ
  • Aug 3, 2021
  • 2 min read

$XBI $124.82 +0.7%

Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!

Covid Updates

$SRNE -1.8% Sorrento Mexico and the National Institute of Genomic Medicine (INMEGEN) of Mexico Government Execute Memorandum of Understanding (MOU) for Rapid Clinical Development of COVID-19 Diagnostics, Therapeutics and Multivalent mRNA-Based Vaccines Against SARS-C. source


$VNDA +0.1% Vanda Pharmaceuticals Closes Enrollment In The ODYSSEY Study Comparing Tradipitant And

Placebo In Hospitalized COVID-19 Pneumonia Patients. source



Pipeline Updates

$KNSA -15.7% Kiniksa Reports Second Quarter 2021 Financial Results and Recent Corporate and Portfolio Activity. source


$LVTX +18.5% on 7/27 LAVA Therapeutics Announces Appointment of Amy Garabedian as General Counsel and Corporate Secretary. source


$MRNA +11.5% Moderna Receives FDA Fast Track Designation for Respiratory Syncytial Virus (RSV) Vaccine (mRNA-1345). source


$MRNS -8.2% Marinus Pharmaceuticals Announces Exclusive Collaboration with Orion Corporation for European Commercialization of Ganaxolone. source


$MRNS -8.2% Marinus Pharmaceuticals Submits New Drug Application (NDA) to FDA for Ganaxolone for the Treatment of Seizures Associated with CDKL5 Deficiency Disorder and Provides Pipeline Update. source


$ARCT +68.1% Arcturus Announces Approval of Singapore Clinical Trial Application to Advance ARCT-154 and ARCT-165, Next Generation STARR™ mRNA Vaccines Targeting SARS-CoV-2 Variants of Concern, in a Phase 1/2 Study. source


$RYTM -4.5% Rhythm Pharmaceuticals Announces Comprehensive Expansion of Clinical Development Program with Five New Phase 2 and 3 Trials Planned to Evaluate Setmelanotide in Rare Genetic Diseases of Obesity. source


$SWTX +0.4% SpringWorks Therapeutics Announces Phase 1b/2a Clinical Trial of Mirdametinib in Patients with Advanced Solid Cancers Harboring MAPK-Activating Mutations. source


$OTLK +6.6% Outlook Therapeutics Reports Positive Efficacy and Safety Data from Pivotal Phase 3 NORSE TWO Trial of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD. source


$ABCL -0.4% Tachyon and AbCellera Collaborate to Develop Novel Antibody Therapeutic Targeting TGF-β Superfamily Member for the Treatment of Cancer. source


$ANGN +4.5% Angion Reports Positive Results from Phase 1 Healthy Volunteer Study for ANG-3070 and FDA Authorization to Initiate Phase 2 Trial in 2021. source



Financial Updates

$CRMD -1.8% INVESTOR ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of CorMedix Inc. (CRMD) Investors. source


$SRRK -11.9% Scholar Rock Announces Leadership Change. source


$TBIO +37.7% Sanofi to Acquire Translate Bio; Advances Deployment of mRNA Technology across Vaccines and Therapeutics Development. source


Posted by FS

 
 
 

Comments

bottom of page